Meeting
2017 Genitourinary Cancers Symposium
Stereotactic body radiotherapy for high-risk prostate cancer (5 Treatment Days): Toxicity results of a phase II trial.
Authors
Amar Upadhyaya Kishan
University of California, Los Angeles, Los Angeles, CA
Amar Upadhyaya Kishan , Donald B. Fuller , Michael L. Steinberg , Victoria Ramirez , Nzhde Agazaryan , Dan Ruan , Minsong Cao , Patrick Kupelian , Christopher R. King
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Localized Disease
Clinical Trial Registration Number
NCT02296229
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 46)
DOI
10.1200/JCO.2017.35.6_suppl.46
Abstract #
46
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase II trial of neoadjuvant gemcitabine/nab-paclitaxel and SBRT for potentially resectable pancreas cancer: An evaluation of acute toxicity.
First Author: Manisha Palta
Poster
2024 ASCO Genitourinary Cancers Symposium
A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
First Author: Ulrich Krafft
Poster
2024 ASCO Genitourinary Cancers Symposium
Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.
First Author: Luca Faustino Valle
Poster
2023 ASCO Annual Meeting
Post radical prostatectomy (RP) PSA outcomes following 6 vs 18 months of perioperative androgen deprivation therapy (ADT) in men with localized high risk prostate cancer (LHRPC): Results of Part 2 of a randomized phase 2 trial.
First Author: Rana R. McKay